KTTA
Pasithea TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Q4 NF1 data could validate dose selection and clinical activity, while the advanced-cancer program's tolerability and durable stable-disease observations preserve optionality for PAS-004.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Dose escalation is ongoing and the maximum tolerated dose has not been established.
Momentum
83
Value
57
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.45 · Bull $1.10 · Bear $0.18
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $3.00
Why
Momentum83 · Δ7d -
Value57 · Δ7d -0.2
Sentiment60 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
83
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.1
Sentiment
60
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 83.4 / Value 56.7 / Sentiment 59.5
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$15.04M
Beta
0.22
Shares Out
33.41M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.26
Rev YoY
-100.0%
EPS YoY
-92.7%
Gross Margin
-21.0%
Op Margin
-
Net Debt
-$55.26M
Current Ratio
35.40
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology